Planta Med 2008; 74(6): 686-692
DOI: 10.1055/s-2008-1074519
Workshop - State of the art in clinical and preclinical studies EPs® 7630 (Umckaloabo®)
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

EPs 7630 Improves Acute Bronchitic Symptoms and Shortens Time to Remission. Results of a Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial

Heinrich Matthys1 , Petra Funk2
  • 1Department of Pneumology, University Hospital Freiburg, Freiburg, Germany
  • 2Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany
Further Information

Publication History

Received: February 5, 2008 Revised: March 19, 2008

Accepted: March 31, 2008

Publication Date:
30 April 2008 (online)

Preview

Abstract

Acute bronchitis commonly associated with cough is predominantly caused by viral infections. The burden on health-care systems and society is enormous. A randomised, placebo-controlled, multicentre clinical trial to investigate the efficacy and safety of a liquid herbal drug preparation from the roots of Pelargonium sidoides (EPs 7630) was conducted in 217 adult outpatients with acute bronchitis. The primary efficacy variable was the bronchitis symptom score (BSS) ranging from 0 to 20. Primary data of this study were already published in 2007. Now, we present further analyses of these already published data combined with new results in order to focus on both the most important features of acute bronchitis and pharmaco-economic aspects of the disease. The BSS decreased by 7.6 ± 2.2 (mean ± SD) points for the active treatment group and 5.3 ± 3.2 points for placebo (p < 0.0001). As compared with placebo, a marked improvement has been shown for EPs 7630 for all disease symptoms (cough, sputum, rales, dyspnoe, pain on coughing, hoarseness, headache, fatigue, fever, limb pain) categorised in severity classes by the patient. Especially strong antitussive and ”anti-fatigue” effects with an early onset during treatment were observed. Patients in the EPs 7630 group were sooner able to work and to a lesser extent confined to bed. In both treatment groups, 3 × 30 drops of the trial medication administered for 7 days were well tolerated. No serious adverse events have been observed. In conclusion, EPs 7630 is superior to placebo in the treatment of acute bronchitis and leads to faster remission of bronchitis related symptoms.

Abbreviations

AE:adverse event

BSS:bronchitis symptom score

GCP:good clinical practice

IMOS:integrative medicine outcomes sclae

IMPSS:integrative medicine patient satisfaction scale

MedDRA:medical dictionary for regulatory activities

SOC:system organ class

TNF:tumour necrosis factor

References

Prof. Dr. med. Heinrich Matthys

Department of Pneumology

University Hospital Freiburg

Hugstetterstrasse 55

79106 Freiburg

Germany

Phone: +49-761-628-22

Fax: +49-761-600-8580

Email: hmatthys@t-online.de